A recombinant IgM antibody targeting HbA1c and its preparation method and application

Through the preparation method of recombinant IgM type antibodies targeting HbA1c, the problems of large batch differences and poor stability of the glycated hemoglobin detection kit are solved, and high specificity and consistency of antibody production is achieved, which improves detection precision and clinical relevance.

CN118772272BActive Publication Date: 2024-11-08NANJING LEADING BIOMEDICAL TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411278384.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-09-12
Publication Date
2024-11-08
Estimated Expiration
2044-09-12

AI Technical Summary

Technical Problem

The existing glycated hemoglobin detection kits vary greatly between batches, and traditional monoclonal antibody preparation processes are difficult to achieve stability and consistency in large-scale production, which affects the detection precision and clinical relevance.

Method used

Recombinant IgM type antibodies targeting HbA1c and their preparation methods are used to construct gene synthesis and expression vectors, express transfected CHO-S cells and undergo efficient purification to ensure the specificity and stability of the antibodies and reduce batch differences.

Benefits of technology

Large-scale production of HbA1c IgM type antibodies with high specificity and consistency has been achieved, which has significantly improved the batch difference, precision and clinical relevance of the kit, and met industrial standards.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118772272B_ABST
    Figure CN118772272B_ABST
Patent Text Reader

Abstract

The present invention relates to the technical field of recombinant antibodies, in particular to a recombinant IgM antibody targeting HbA1c and a preparation method and application thereof, wherein the heavy chain sequence of the recombinant IgM antibody is shown in SEQ ID NO: 1, and the light chain sequence is shown in SEQ ID NO: 2. The recombinant IgM antibody targeting HbA1c of the present invention can realize the large-scale production of HbA1c key raw material antibodies, and the difference between antibody batches is small, and the stability and consistency are both high, which meets the industrial use standards. Moreover, the kit prepared by using the recombinant IgM antibody targeting HbA1c of the present invention shows significant advantages in various performances such as batch difference, precision, clinical relevance and stability.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of recombinant antibody technology, and specifically relates to a recombinant IgM antibody targeting HbA1c and a preparation method and application thereof. Background Art

[0002] Diabetes is a chronic disease. The diagnostic indicators of diabetes mainly include fasting blood glucose (FPG) and oral glucose tolerance test (OGTT). FPG alone may lead to missed diagnosis. Although OGTT is the gold standard, it is cumbersome to operate, has poor repeatability, and is affected by many factors.

[0003] Normal hemoglobin (Hb) mainly includes HbA1 bound to sugar and HbA0 not bound to sugar. In HbA1, HbA1c accounts for about 80% of HbA1. The International Federation of Clinical Chemistry (IFCC) defines HbA1c as a stable, irreversible tetrameric compound (N-1-deoxyfructose-Hb) formed by the amino termini of one or two β chains on Hb and glucose. The description of HbA1c in the 2023 edition of the American Diabetes Association Diabetes Diagnosis and Treatment Standards is that non-pregnant diabetic patients should aim for <7%.

[0004] There are many methodologies for detecting glycated hemoglobin, and each has its own characteristics. In terms of the accuracy of the test results, capillary electrophoresis is the best, but it is slow to operate and rarely used in clinical practice; affinity chromatography is also highly accurate, but it has high requirements for the selected affinity substances; in terms of the convenience of the detection method, both the immunoassay and the enzyme method can be implemented on a fully automatic biochemical analyzer, so the throughput is high and the measurement speed is fast; the immunoassay is relatively resistant to interference from most common Hb variants, such as HbS\HbAC\HbAE. The stability of the enzyme method has high requirements for light, temperature, etc., and its precision is slightly worse than that of the immunoassay. In summary, the immunoassay is the preferred method for clinical detection of glycated hemoglobin. The principle is that the HbA1c antibody specifically recognizes the amino-terminal 4-8 amino acids of the glycated hemoglobin β-globin, thereby forming an antigen-antibody complex, thereby changing the absorbance.

[0005] At present, the domestic glycated hemoglobin test has not yet been standardized. In addition, the glycated hemoglobin immunoassay kits on the market have some problems: insufficient precision, clinical relevance needs to be optimized, and large differences between production batches.

[0006] In the production process of in vitro diagnostic reagents, the batch-to-batch reproducibility of the product is crucial. Antibodies are one of the key raw materials for immunoassay reagents, and the performance differences between different batches will directly affect the quality of the kit. The immunoassay method for preparing mouse monoclonal antibodies is easily affected by individual differences in animals, and the ascites volume of mice is limited, resulting in limited single-batch production. Therefore, it is difficult to prepare large quantities of antibodies with stable performance between batches using traditional monoclonal antibody preparation processes.

[0007] As for the antibodies required for the glycated hemoglobin detection reagent, the HbA1c detection kits of most manufacturers on the market are currently prepared by combining monoclonal antibodies and polyclonal antibodies, but in the production process of this reagent, two materials are identified as key materials, namely monoclonal antibodies and polyclonal antibodies, and the production risk is high and the performance is limited. CN116284370A discloses a method for preparing a monoclonal antibody for glycated hemoglobin and a method for assembling it into an IgM-like antibody by cross-linking it with glutaraldehyde. Although this method is more convenient than the previous monoclonal antibody and polyclonal antibody combination methodology, it can achieve high precision and accuracy evaluation of glycated hemoglobin without using polyclonal antibodies, but in the actual production process, it is found that the antibody obtained by cross-linking oligomers with glutaraldehyde has a large batch difference.

[0008] Therefore, there is an urgent need in the art to develop a method for preparing an IgM antibody targeting HbA1c, which can effectively avoid the batch-to-batch difference caused by the cross-linking process, thereby reducing the batch-to-batch difference in the production and preparation of the detection reagent. Summary of the invention

[0009] The object of the present invention is to provide a recombinant IgM antibody targeting HbA1c and a preparation method and application thereof.

[0010] To achieve the above object, the present invention provides the following technical solutions:

[0011] A recombinant IgM antibody targeting HbA1c, wherein the heavy chain sequence is shown in SEQ ID NO:1, and the light chain sequence is shown in SEQ ID NO:2.

[0012] A method for preparing a recombinant IgM antibody targeting HbA1c comprises the following steps:

[0013] (1) Construction of expression vectors for IgM antibody heavy and light chain sequences

[0014] The heavy chain and light chain sequences were synthesized by gene synthesis, and then the gene fragments were connected into the vector pCMV; wherein the heavy chain sequence is shown in SEQ ID NO: 1, and the light chain sequence is shown in SEQ ID NO: 2;

[0015] (2) Cell transfection and expression

[0016] The constructed expression vector was transfected into the mammalian cell line CHO-S cell line expression system.

[0017] (3) Selecting cell lines that efficiently express IgM antibodies;

[0018] (4) IgM antibody purification

[0019] 1) Dilute the clarified antibody stock solution 1:1 with 2X binding buffer;

[0020] 2) When loading the sample for the first time, add excess antibody stock solution and retain the waste liquid flowing out of the column;

[0021] 3) After loading, collect and retain the original liquid flowing out of the column and the liquid from the first column wash; wash the column with binding buffer until the monitor returns to the baseline;

[0022] 4) Elute the bound antibody with elution buffer;

[0023] 5) Based on the estimated amount of antibody in the stock solution, all or part of the collected effluent is re-applied to the column according to the previous separation procedure;

[0024] 6) Wash away unbound material with binding buffer. When the monitor returns to baseline, elute the antibody directly into the equilibrium buffer.

[0025] 7) When all antibodies have been eluted and the monitor has returned to baseline, add binding buffer to the column;

[0026] 8) Store the eluted and neutralized antibodies at 4°C for merging with the purified IgM.

[0027] 9) Continue loading and eluting bound antibodies until all antibodies are purified;

[0028] 10) Pool all eluted antibodies and dialyze against dialysis buffer to further concentrate the antibodies.

[0029] Wherein, the binding buffer is 10 mmol / L phosphate buffer containing 0.5 mol / L NaCl, pH 7.2; the 2X binding buffer is 20 mmol / L phosphate buffer containing 1 mol / L NaCl, pH 7.2.

[0030] Wherein, the elution buffer is 100 mmol / L glycine containing 150 mmol / L NaCl, pH 2.4.

[0031] The equilibration buffer was 1.0 mol / L Tris, and the dialysis buffer was 150 mmol / L PBS solution, pH 7.6.

[0032] The recombinant IgM antibody targeting HbA1c of the present invention can be used to prepare an HbA1c detection kit, wherein the concentration of the recombinant IgM antibody is 0.01-0.02 g / L.

[0033] Compared with the prior art, the present invention has the following beneficial effects:

[0034] The present invention provides a recombinantly expressed high-specificity HbA1c IgM antibody, which accurately locks its gene sequence, ensures the specificity of the antibody, and realizes the large-scale production of the key raw material antibody of HbA1c. The antibody has small differences between batches, high stability and consistency, and meets the industrial use standards.

[0035] The present invention uses the recombinant HbA1c IgM antibody to prepare a detection kit. Through comparison of various performances, it is found that the kit prepared using the recombinant HbA1c IgM antibody of the present invention shows significant advantages in various performances such as batch difference, precision, clinical relevance and stability. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] Figure 1 Schematic diagram for constructing expression vector;

[0037] Figure 2 is the clinical relevance result of test kit A;

[0038] Figure 3 is the clinical relevance result of test kit B;

[0039] Figure 4 It is the stability result of test kit A;

[0040] Figure 5 The stability results of test kit B are shown in Figure 2. DETAILED DESCRIPTION

[0041] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0042] Example 1 Recombinant IgM Antibody Targeting HbA1c

[0043] The antibody is a pentamer with a molecular weight of 950 kD, including a heavy chain constant region, a heavy chain variable region, a light chain variable region and a light chain constant region. The variable regions of the heavy chain and light chain are from the HbA1c monoclonal antibody in CN116284370A, and the constant region is cloned from a mouse IgM antibody. The specific preparation steps are as follows:

[0044] (1) Synthesis of IgM antibody heavy chain and light chain sequences

[0045] IgM antibodies differ from IgG antibodies in structure, most notably in that IgM is a pentamer or hexamer, while IgG is usually a monomer. Therefore, the heavy and light chain genes of IgG antibodies need to be modified to adapt to the structure of IgM, and the heavy chain gene of IgG is replaced with the heavy chain gene of IgM, and the J chain gene is introduced, because IgM needs the J chain to form a multimeric structure.

[0046] Heavy chain sequence (shown in SEQ ID NO: 1):

[0047] MEQYNSTYRVVCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIA VEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKIVLTQSPASLAVSL SQSFPNVFPLVSCESPLSDKNLVAMGCLARDFLPSTISFTWNYQNNTEVIQGIRTFPTLRTGGKYLATSQVLLSPKSILEGSDEYLVCKIHYGGKNRDLHVPIPAVAEMNPNV NVFVPRDGFSGPAPRKSKLICEATNFTPKPITVSWLKDGKLVESGFTTDPVTIENKGSTPQTYKVISTLTISEIDWLNLNVYTCRVDHRGLTFLKNVSSTCAASPSTDILTFT IPPSFADIFLSKSANLTCLVSNLATYETLNISWASQSGEPLETKIKIMESHPNGTFSAKGVASVCVEDWNNRKEFVCTVTHRDLPSPQKKFISKPNEVHKHPPAVYLLPPARE QLNLRESATVTCLVKGFSPADISVQWLQRGQLLPQEKYVTSAPMPEPGAPGFYFTHSILTVTEEEWNSGETYTCVVGHEALPHLVTERTVDKSTGKPTLYNVSLIMSDTGGTCY MKTHLLLWGV LAIFVKVVLVTGDDEATILADNKCMCTRVTSKIIPSTEDPNEDIVERNIRIVVPLNNRENISDPTSPLRRNFVYHLS DVCKKCDPVEVELEDQVVTATQSNICNEDDGVPETCYMYDRNKCYTTMVPLRYHGETKMVQAALTPDSCYPD

[0048] Note: The underlined sequence at the front is the variable region sequence, the underlined sequence at the back is the J chain sequence, and the sequence in the middle is the constant region sequence.

[0049] Light chain sequence (shown in SEQ ID NO: 2):

[0050] PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGIIHPVEEEDAATYYCQHIRGAYTFGGGTKLEIKRMDWTWRFLFVVASVTVSCKASGGTFSNYAISWVRQAPGQGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREAATGVQSQMQVVQSGAEVKKPGS

[0051] Note: The underlined sequence is the variable region sequence, and the rest is the constant region sequence.

[0052] (2) Construction of expression vectors for IgM antibody heavy chain and light chain sequences

[0053] The heavy chain and light chain sequences were synthesized by gene synthesis, and then the gene synthesis company was asked to directly connect the gene fragments into the vector pCMV, such as Figure 1 shown.

[0054] (3) Cell transfection and expression

[0055] The constructed expression vector was introduced into the mammalian cell line CHO-S for expression. One day before transfection, CHO-S cells were cultured at 5×10 5 The cells were inoculated at a density of 10 cells / mL in 30 mL of CD-FortiCHO medium containing 6 mmol / L L-glutamine, and the cells were cultured on a shaker at 37°C, 8% CO2, and 100 r / min. On the day of transfection, the FreeStyleTM MAX transfection kit was used according to the instructions. 48 hours after transfection, the cells were pressure-screened using a screening system with different concentrations of puromycin (5, 10, 20 µg / mL) and corresponding different concentrations of methotrexate (50, 100, 200 nmol / L). After the cells were statically cultured for 7 days, they were passaged into 125 mL shake flasks. When the cell viability exceeded 90% and the cell density reached 1×10 6 The first stage of screening was completed when the cell viability reached 1.544 cells / mL. Subsequently, the cells were subjected to the second stage of pressure screening using the screening system of 30 µg / mL puromycin + 500 nmol / L methotrexate and 50 µg / mL puromycin + 1000 nmol / L methotrexate, and the cells were passaged every 3 days until the cell viability reached more than 90%, and the screening process was completed.

[0056] (4) Screening and optimization

[0057] Cloning medium was prepared by limiting dilution method: 1% anti-aggregating agent and 6 mmol / L L-glutamine were added to CD-FortiCHO medium. The experiment was divided into two groups, one was unstressed condition (cloning medium only), and the other was stressed condition (150 nmol / L puromycin and methotrexate were added to the cloning medium). Cells were seeded into 96-well plates at a density of 0.5 cells per well (30 plates per group) and cultured statically for 14 days. During this period, the growth of monoclonal colonies was monitored using a monoclonal imager, and the monoclonal formation rate was calculated. The cell supernatant was screened by enzyme-linked immunosorbent assay (ELISA), and the top 150 clones with the highest expression were selected and transferred to 24-well plates, and then amplified to 6-well plates in sequence. After isodensity evaluation in 6-well plates, the top 15 clones with the highest expression were transferred to 125 mL shake flasks for fed-batch evaluation. The specific operation is: stable cell lines (activity ≥ 90%) are cultured at 3×10 5 30 mL was inoculated into a 125 mL culture flask at a density of cells / mL. Feeds (4.5% Feed A + 0.45% Feed B) were added on days 3, 5, 7, 9, and 11. The glucose concentration was measured on days 4, 6, 8, and 10, and glucose was supplemented to maintain its concentration at 5 g / L. The culture was harvested when the survival rate dropped below 50%. Feed A is CHO CD EfficientFeed™ A nutrient additive; Feed B is CHO CD EfficientFeed™ B liquid nutrient supplement, both purchased from Gibco.

[0058] (5) IgM antibody purification

[0059] 5.1 Material preparation

[0060] Binding buffer: 10 mmol / L phosphate buffer containing 0.5 mol / L NaCl, pH 7.2;

[0061] 2X binding buffer: 20 mmol / L phosphate buffer containing 1 mol / L NaCl, pH 7.2;

[0062] Elution buffer: 100 mmol / L glycine containing 150 mmol / L NaCl, pH 2.4;

[0063] Equilibration buffer: 1.0 mol / L Tris;

[0064] Dialysis buffer: 150 mmol / L PBS solution, pH 7.6;

[0065] Prepare the purification column by pouring the cross-linked mouse anti-human IgM antibody agarose resin into a clean glass column. When the beads are precipitated, rinse with binding buffer and wash the homogenate with several column volumes of binding buffer. When the A280 monitor shows that the absorbance of the eluate reaches the horizontal baseline, the column is ready for use.

[0066] 5.2 Operation steps

[0067] 1) Dilute the clarified antibody stock 1:1 with 2X Binding Buffer.

[0068] 2) When loading the sample for the first time, add excess antibody stock solution and retain the waste liquid flowing out of the column.

[0069] 3) After loading, collect and retain the original solution flowing out of the column and the liquid from the first column wash. Wash the column with binding buffer until the monitor returns to the baseline.

[0070] 4) Elute the bound antibody with elution buffer. Use an ultra-micro-volume UV spectrophotometer to measure A280 and calculate the sample concentration based on the extinction coefficient of IgM antibody, 1.18 L / mol·cm.

[0071] 5) Based on the estimate of the amount of antibody contained in the original solution, all or part of the collected effluent is re-applied to the column according to the previous separation procedure.

[0072] 6) Wash away unbound material with binding buffer and when the monitor returns to baseline, elute the antibody directly into equilibration buffer.

[0073] 7) When all the antibodies have been eluted and the monitor has returned to baseline, add binding buffer to the column.

[0074] 8) Store the eluted and neutralized antibodies at 4°C for combining with the re-purified IgM.

[0075] 9) Continue loading and eluting bound antibody until all antibody is purified.

[0076] 10) Pool all eluted antibodies and further concentrate the antibody to approximately 2 mg / mL using dialysis buffer.

[0077] Example 2 Preparation of HbA1c Detection Kit Using HbA1c IgM Antibody (Latex Immunoturbidimetry)

[0078] The HbA1c detection kit (hereinafter collectively referred to as detection kit A) prepared using HbA1c IgM antibody includes:

[0079] Reagent R1:

[0080] 25 mM glycine buffer (pH 8.2); latex particles (average particle size: about 130 nm).

[0081] Reagent R2:

[0082] 25 mM glycine buffer (pH 6.2); 500 mM sodium chloride; 0.06% Tween 20; 0.1% sodium azide; 0.01-0.02 g / L of the HbA1c IgM antibody prepared in Example 1.

[0083] Testing instrument: Hitachi 7180 fully automatic biochemical analyzer

[0084] parameter:

[0085] Sample volume: 4 μL

[0086] Reagent R1: 150 μL

[0087] Reagent R2: 50 μL

[0088] Fitting method: Spline

[0089] Dominant wavelength: 660 nm

[0090] Sub-wavelength: None.

[0091] Comparative Example Preparation of HbA1c Detection Kit Using HbA1c Monoclonal Antibody Oligomer (Latex Immuno-Turbidimetry)

[0092] The HbA1c detection kit prepared using HbA1c monoclonal antibody oligomer (hereinafter collectively referred to as detection kit B) includes:

[0093] Reagent R1:

[0094] 25 mM glycine buffer (pH 8.2); latex particles (average particle size: about 130 nm).

[0095] Reagent R2:

[0096] 25 mM glycine buffer (pH 6.2); 500 mM sodium chloride; 0.06% Tween 20; 0.1% sodium azide; HbA1c oligomer 0.03-0.04 g / L (Nanjing Liding Medical Technology Co., Ltd.).

[0097] Testing instrument: Hitachi 7180 fully automatic biochemical analyzer

[0098] parameter:

[0099] Sample volume: 4 μL

[0100] Reagent R1: 150 μL

[0101] Reagent R2: 50 μL

[0102] Fitting method: Spline

[0103] Dominant wavelength: 660 nm

[0104] Sub-wavelength: None.

[0105] A comparative experiment was conducted on the detection kit of Example 2 and the comparative example, as follows:

[0106] (1) Comparison of inter-batch differences

[0107] Three batches of HbA1c IgM antibodies and HbA1c oligomers were produced respectively, and then two HbA1c detection kits (i.e., detection kit A and detection kit B) were prepared. 16 samples were tested simultaneously using the 7180 kit, and the ΔAbs relative deviation was calculated.

[0108] Table 1 Batch variation of test kit A

[0109]

[0110] Table 2 Batch variation of test kit B

[0111]

[0112] (2) Precision comparison

[0113] Two HbA1c test kits were used to repeat the test 10 times for low-value (5.4%) and high-value (12.8%) samples, and repeatability analysis was performed. The coefficient of variation CV (%) = SD / mean × 100%, and the industry standard requires that CV should be less than 3%. The coefficient of variation CV of test reagent B can be less than 2%, while the coefficient of variation CV of test reagent A is less than 1%.

[0114] Table 3 Precision comparison (left side is test kit A, right side is test kit B)

[0115]

[0116] (3) Comparison of clinical relevance

[0117] like Figures 2-3 As shown, two HbA1c detection kits were used to test 40 clinical samples, 5 EQA samples, 2 Randox quality control samples, and 2 Bio-Rad quality control samples using Hitachi 7180 biochemical analyzer, and compared with HPLC measurements, the correlation coefficients were all greater than 0.9900; in comparison, the clinical correlation of detection kit A was better than that of detection kit B prepared with monoclonal antibody oligomers.

[0118] (4) Stability comparison

[0119] like Figures 4-5 As shown, the two HbA1c detection kits were placed at 37°C for heat breaking, and then the synchronous method was used to detect and calculate the relative deviation of the reactivity of the samples tested at 4°C and 37°C. The results showed that the kit prepared with HbA1c IgM antibody can be stable for a longer time at 37°C.

[0120] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A recombinant IgM antibody targeting HbA1c, Features: The heavy chain sequence is shown in SEQ ID NO:1, and the light chain sequence is shown in SEQ ID NO:

2.

2. The method for preparing the recombinant IgM antibody targeting HbA1c according to claim 1, It is characterized in that The following steps are involved: (1) Construction of expression vectors for IgM antibody heavy and light chain sequences The heavy chain and light chain sequences were synthesized by gene synthesis, and then the gene fragments were connected into the vector pCMV; wherein the heavy chain sequence is shown in SEQ ID NO: 1, and the light chain sequence is shown in SEQ ID NO: 2; (2) Cell transfection and expression (3) Selecting cell lines that efficiently express IgM antibodies; (4) IgM antibody purification.

3. The method for preparing a recombinant IgM antibody targeting HbA1c according to claim 2, Features: The step (2) is to transfect the constructed expression vector into the mammalian cell line CHO-S cell line expression system.

4. The method for preparing a recombinant IgM antibody targeting HbA1c according to claim 2, Features: The specific method of step (4) is: 1) Dilute the clarified antibody stock solution 1:1 with 2X binding buffer; 2) When loading the sample for the first time, add an excess of antibody stock solution and retain the waste liquid flowing out of the column; wherein the preparation method of the purification column is as follows: prepare the purification column, pour the agarose resin of the cross-linked mouse anti-human IgM antibody into a clean glass column; 3) After loading, collect and retain the original liquid flowing out of the column and the liquid from the first column wash; wash the column with binding buffer until the monitor returns to the baseline; 4) Elute the bound antibody with elution buffer; 5) Based on the estimated amount of antibody in the stock solution, re-load the collected effluent onto the column according to the separation procedure; 6) Wash away unbound material with binding buffer, and when the monitor returns to baseline, elute the antibody directly into the equilibrium buffer; 7) When all antibodies have been eluted and the monitor has returned to baseline, add binding buffer to the column; 8) Store the eluted and neutralized antibodies at 4°C for merging with the purified IgM. 9) Continue loading and eluting bound antibodies until all antibodies are purified; 10) Pool all eluted antibodies and further concentrate the antibodies using dialysis buffer.

5. The method for preparing a recombinant IgM antibody targeting HbA1c according to claim 4, Features: The binding buffer is 10 mmol / L phosphate buffer containing 0.5 mol / L NaCl, pH 7.2; the 2X binding buffer is 20 mmol / L phosphate buffer containing 1 mol / L NaCl, pH 7.

2.

6. The method for preparing a recombinant IgM antibody targeting HbA1c according to claim 4, Features: The elution buffer is 100 mmol / L glycine containing 150 mmol / L NaCl, pH 2.

4.

7. The method for preparing a recombinant IgM antibody targeting HbA1c according to claim 4, Features: The equilibration buffer was 1.0 mol / L Tris; the dialysis buffer was 150 mmol / L PBS solution, pH 7.

6.

8. Use of the recombinant IgM antibody targeting HbA1c according to claim 1 in the preparation of an HbA1c detection kit.

9. Use of the recombinant IgM antibody targeting HbA1c according to claim 8 in the preparation of an HbA1c detection kit, Features: The concentration of recombinant IgM antibody is 0.01-0.02 g / L.